Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 666 entries
Sorted by: Best Match Show Resources per page
Not such a complainer anymore: Confrontation that signals a growth mindset can attenuate backlash

Growth Mindset STEM Intervention

Arnett R, Brown X, Kroeper K, Rattan A.
GSID: WmY7-LEVc9MJ
A Rattan, K Kroeper, R Arnett, X Brown… - Journal of Personality …, 2023 - psycnet.apa.org

… confrontations might also represent a new avenue for mindset interventions, in the context of bias … Growing STEM: Perceived faculty mindset as an indicator of communal affordances in …

Cite
Rattan, A., Kroeper, K., Arnett, R., Brown, X., & Murphy, M. (2023). Not such a complainer anymore: Confrontation that signals a growth mindset can attenuate backlash. Journal of Personality and Social Psychology, 124(2), 344.
Rattan, Aneeta, et al. "Not such a complainer anymore: Confrontation that signals a growth mindset can attenuate backlash." Journal of Personality and Social Psychology 124.2 (2023): 344.
Copy Download .nbib Format: MLA
Not such a complainer anymore: Confrontation that signals a growth mindset can attenuate backlash

Growth Mindset

Arnett R, Brown X, Kroeper K, Rattan A.
GSID: 74qbHJ9ZbtMJ
A Rattan, K Kroeper, R Arnett, X Brown… - Journal of Personality …, 2022 - psycnet.apa.org

… If confrontation signals a growth mindset, as we theorize, we wondered whether this … has a more growth mindset, may also emerge. We propose and test whether these growth mindset …

Cite
Rattan, A., Kroeper, K., Arnett, R., Brown, X., & Murphy, M. (2022). Not such a complainer anymore: Confrontation that signals a growth mindset can attenuate backlash. Journal of Personality and Social Psychology.
Rattan, Aneeta, et al. "Not such a complainer anymore: Confrontation that signals a growth mindset can attenuate backlash." Journal of Personality and Social Psychology (2022).
Copy Download .nbib Format: MLA
How many raters? Toward the most reliable diagnostic consensus.

Statistics in medicine

Kraemer HC.
PMID: 1609173
Stat Med. 1992 Feb 15;11(3):317-31. doi: 10.1002/sim.4780110305.

When faced with a decision whether or not to treat a patient, to enter or to withdraw a patient from a clinical trial, or any other such binary decision, based on diagnosis with unsatisfactory reliability, can a consensus diagnosis...

Cite
Kraemer HC. How many raters? Toward the most reliable diagnostic consensus. Stat Med. 1992;11(3):317-31doi: 10.1002/sim.4780110305.
Kraemer, H. C. (1992). How many raters? Toward the most reliable diagnostic consensus. Statistics in medicine, 11(3), 317-31. https://doi.org/10.1002/sim.4780110305
Kraemer, H C. "How many raters? Toward the most reliable diagnostic consensus." Statistics in medicine vol. 11,3 (1992): 317-31. doi: https://doi.org/10.1002/sim.4780110305
Kraemer HC. How many raters? Toward the most reliable diagnostic consensus. Stat Med. 1992 Feb 15;11(3):317-31. doi: 10.1002/sim.4780110305. PMID: 1609173.
Copy Download .nbib Format: NLM
Doubling the blockade for melanoma immunotherapy.

Oncoimmunology

Galluzzi L, Eggermont A, Kroemer G.
PMID: 26942094
Oncoimmunology. 2015 Oct 29;5(1):e1106127. doi: 10.1080/2162402X.2015.1106127. eCollection 2016.

No abstract available.

Cite
Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology. 2015;5(1):e1106127doi: 10.1080/2162402X.2015.1106127.
Galluzzi, L., Eggermont, A., & Kroemer, G. (2016). Doubling the blockade for melanoma immunotherapy. Oncoimmunology, 5(1), e1106127. https://doi.org/10.1080/2162402X.2015.1106127
Galluzzi, Lorenzo, et al. "Doubling the blockade for melanoma immunotherapy." Oncoimmunology vol. 5,1 (2016): e1106127. doi: https://doi.org/10.1080/2162402X.2015.1106127
Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology. 2015 Oct 29;5(1):e1106127. doi: 10.1080/2162402X.2015.1106127. eCollection 2016. PMID: 26942094; PMCID: PMC4760293.
Copy Download .nbib Format: NLM
Trial watch: Naked and vectored DNA-based anticancer vaccines.

Oncoimmunology

Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 26155408
Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May.

One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is...

Cite
Bloy N, Buqué A, Aranda F, et al. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015;4(5):e1026531doi: 10.1080/2162402X.2015.1026531.
Bloy, N., Buqué, A., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology, 4(5), e1026531. https://doi.org/10.1080/2162402X.2015.1026531
Bloy, Norma, et al. "Trial watch: Naked and vectored DNA-based anticancer vaccines." Oncoimmunology vol. 4,5 (2015): e1026531. doi: https://doi.org/10.1080/2162402X.2015.1026531
Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May. PMID: 26155408; PMCID: PMC4485755.
Copy Download .nbib Format: NLM
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark.

Oncoimmunology

Kroemer G, Galluzzi L.
PMID: 26140249
Oncoimmunology. 2015 Jun 03;4(7):e1058037. doi: 10.1080/2162402X.2015.1058037. eCollection 2015 Jul.

Results from recent clinical trials demonstrate that a combinatorial immunotherapeutic regimen based on 2 distinct checkpoint blockers, namely, the CTLA4-targeting agent ipilimumab and the PD-1-specific molecule nivolumab, causes objective responses in a majority of subjects with advanced melanoma. These...

Cite
Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology. 2015;4(7):e1058037doi: 10.1080/2162402X.2015.1058037.
Kroemer, G., & Galluzzi, L. (2015). Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology, 4(7), e1058037. https://doi.org/10.1080/2162402X.2015.1058037
Kroemer, Guido, and Galluzzi, Lorenzo. "Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark." Oncoimmunology vol. 4,7 (2015): e1058037. doi: https://doi.org/10.1080/2162402X.2015.1058037
Kroemer G, Galluzzi L. Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology. 2015 Jun 03;4(7):e1058037. doi: 10.1080/2162402X.2015.1058037. eCollection 2015 Jul. PMID: 26140249; PMCID: PMC4485790.
Copy Download .nbib Format: NLM
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?.

Oncoimmunology

Kroemer G, Galluzzi L, Zitvogel L, Fridman WH.
PMID: 26140250
Oncoimmunology. 2015 Jun 05;4(7):e1058597. doi: 10.1080/2162402X.2015.1058597. eCollection 2015 Jul.

The first study demonstrating that human colorectal carcinoma (CRC) is under robust immunosurveillance was published a decade ago. Today, it is clear that CRC patients with Stage III lesions abundantly infiltrated by effector memory T cells have a better...

Cite
Kroemer G, Galluzzi L, Zitvogel L, et al. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. Oncoimmunology. 2015;4(7):e1058597doi: 10.1080/2162402X.2015.1058597.
Kroemer, G., Galluzzi, L., Zitvogel, L., & Fridman, W. H. (2015). Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. Oncoimmunology, 4(7), e1058597. https://doi.org/10.1080/2162402X.2015.1058597
Kroemer, Guido, et al. "Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?." Oncoimmunology vol. 4,7 (2015): e1058597. doi: https://doi.org/10.1080/2162402X.2015.1058597
Kroemer G, Galluzzi L, Zitvogel L, Fridman WH. Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. Oncoimmunology. 2015 Jun 05;4(7):e1058597. doi: 10.1080/2162402X.2015.1058597. eCollection 2015 Jul. PMID: 26140250; PMCID: PMC4485723.
Copy Download .nbib Format: NLM
[No title available]

Wilhelm Roux' Archiv fur Entwicklungsmechanik der Organismen

Kroeger H.
PMID: 28354740
Wilhelm Roux Arch Entwickl Mech Org. 1959 Jan;151(2):113-135. doi: 10.1007/BF00576375.

No abstract available.

Cite
Kroeger H. Determinationsmosaike aus kombiniert implantierten Imaginalscheiben vonEphestia kühniella Zeller. . Wilhelm Roux Arch Entwickl Mech Org. 1959;151(2):113-135doi: 10.1007/BF00576375.
Kroeger, H. (1959). Determinationsmosaike aus kombiniert implantierten Imaginalscheiben vonEphestia kühniella Zeller. . Wilhelm Roux' Archiv fur Entwicklungsmechanik der Organismen, 151(2), 113-135. https://doi.org/10.1007/BF00576375
Kroeger, Heinrich. "Determinationsmosaike aus kombiniert implantierten Imaginalscheiben vonEphestia kühniella Zeller." . Wilhelm Roux' Archiv fur Entwicklungsmechanik der Organismen vol. 151,2 (1959): 113-135. doi: https://doi.org/10.1007/BF00576375
Kroeger H. Determinationsmosaike aus kombiniert implantierten Imaginalscheiben vonEphestia kühniella Zeller. . Wilhelm Roux Arch Entwickl Mech Org. 1959 Jan;151(2):113-135. doi: 10.1007/BF00576375. German. PMID: 28354740.
Copy Download .nbib Format: NLM
Modeling non-hereditary mechanisms of Alzheimer disease during apoptosis in yeast.

Microbial cell (Graz, Austria)

Braun RJ, Sommer C, Leibiger C, Gentier RJ, Dumit VI, Paduch K, Eisenberg T, Habernig L, Trausinger G, Magnes C, Pieber T, Sinner F, Dengjel J, Leeuwen FW, Kroemer G, Madeo F.
PMID: 28357285
Microb Cell. 2015 Mar 20;2(4):136-138. doi: 10.15698/mic2015.04.199.

Impaired protein degradation and mitochondrial dysfunction are believed to contribute to neurodegenerative disorders, including Alzheimer disease (AD). In patients suffering from non-hereditary AD, UBB

Cite
Braun RJ, Sommer C, Leibiger C, et al. Modeling non-hereditary mechanisms of Alzheimer disease during apoptosis in yeast. Microb Cell. 2015;2(4):136-138doi: 10.15698/mic2015.04.199.
Braun, R. J., Sommer, C., Leibiger, C., Gentier, R. J., Dumit, V. I., Paduch, K., Eisenberg, T., Habernig, L., Trausinger, G., Magnes, C., Pieber, T., Sinner, F., Dengjel, J., Leeuwen, F. W., Kroemer, G., & Madeo, F. (2015). Modeling non-hereditary mechanisms of Alzheimer disease during apoptosis in yeast. Microbial cell (Graz, Austria), 2(4), 136-138. https://doi.org/10.15698/mic2015.04.199
Braun, Ralf J, et al. "Modeling non-hereditary mechanisms of Alzheimer disease during apoptosis in yeast." Microbial cell (Graz, Austria) vol. 2,4 (2015): 136-138. doi: https://doi.org/10.15698/mic2015.04.199
Braun RJ, Sommer C, Leibiger C, Gentier RJ, Dumit VI, Paduch K, Eisenberg T, Habernig L, Trausinger G, Magnes C, Pieber T, Sinner F, Dengjel J, Leeuwen FW, Kroemer G, Madeo F. Modeling non-hereditary mechanisms of Alzheimer disease during apoptosis in yeast. Microb Cell. 2015 Mar 20;2(4):136-138. doi: 10.15698/mic2015.04.199. PMID: 28357285; PMCID: PMC5348975.
Copy Download .nbib Format: NLM
[No title available]

Microbial cell (Graz, Austria)

Sixt BS, Valdivia RH, Kroemer G.
PMID: 28357396
Microb Cell. 2017 Mar 02;4(3):101-104. doi: 10.15698/mic2017.03.564.

Bacteria of the phylum

Cite
Sixt BS, Valdivia RH, Kroemer G. . Microb Cell. 2017;4(3):101-104doi: 10.15698/mic2017.03.564.
Sixt, B. S., Valdivia, R. H., & Kroemer, G. (2017). . Microbial cell (Graz, Austria), 4(3), 101-104. https://doi.org/10.15698/mic2017.03.564
Sixt, Barbara S, et al. "." Microbial cell (Graz, Austria) vol. 4,3 (2017): 101-104. doi: https://doi.org/10.15698/mic2017.03.564
Sixt BS, Valdivia RH, Kroemer G. . Microb Cell. 2017 Mar 02;4(3):101-104. doi: 10.15698/mic2017.03.564. PMID: 28357396; PMCID: PMC5349196.
Copy Download .nbib Format: NLM
Roulette gamblers and gamblers at electronic game machines: Where are the differences?.

Journal of gambling studies

Kroeber HL.
PMID: 24243283
J Gambl Stud. 1992 Mar;8(1):79-92. doi: 10.1007/BF01881470.

In an unselected group of 46 excessive gamblers who came for psychiatric help or for an expert opinion on legal responsibility, two different groups of gamblers are compared: roulette gamblers and those who played at German-style slot machines. In...

Cite
Kroeber HL. Roulette gamblers and gamblers at electronic game machines: Where are the differences?. J Gambl Stud. 1992;8(1):79-92doi: 10.1007/BF01881470.
Kroeber, H. L. (1992). Roulette gamblers and gamblers at electronic game machines: Where are the differences?. Journal of gambling studies, 8(1), 79-92. https://doi.org/10.1007/BF01881470
Kroeber, H L. "Roulette gamblers and gamblers at electronic game machines: Where are the differences?." Journal of gambling studies vol. 8,1 (1992): 79-92. doi: https://doi.org/10.1007/BF01881470
Kroeber HL. Roulette gamblers and gamblers at electronic game machines: Where are the differences?. J Gambl Stud. 1992 Mar;8(1):79-92. doi: 10.1007/BF01881470. PMID: 24243283.
Copy Download .nbib Format: NLM
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Oncoimmunology

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25949870
Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan.

An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal...

Cite
Vacchelli E, Pol J, Bloy N, et al. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4(1):e985940doi: 10.4161/2162402X.2014.985940.
Vacchelli, E., Pol, J., Bloy, N., Eggermont, A., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology, 4(1), e985940. https://doi.org/10.4161/2162402X.2014.985940
Vacchelli, Erika, et al. "Trial watch: Tumor-targeting monoclonal antibodies for oncological indications." Oncoimmunology vol. 4,1 (2015): e985940. doi: https://doi.org/10.4161/2162402X.2014.985940
Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan. PMID: 25949870; PMCID: PMC4368132.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 666 entries